Transarterial chemoembolization (TACE) improves survival in cirrhotic patients with hepatocellular carcinoma (HCC). The optimal schedule, best anticancer agent and best technique are still unclear.

A multicenter, phase 2 study of atezolizumab plus bevacizumab (atezo+bev) combination therapy in patients with unresectable hepatocellular carcinoma (HCC) and Child–Pugh class B cirrhosis: CHALLENGE ...

Variations in tumor biology from patient to patient combined with the low overall survival rate of hepatocellular carcinoma (HCC) present significant clinical challenges. During the progression of ...

This document, on the diagnosis and treatment of patients with hepatocellular carcinoma (HCC), was commissioned by the British Society of Gastroenterology as part of a wider initiative to develop ...

Introduction: The care for patients with hepatocellular carcinoma (HCC) is challenging. This study is to evaluate the effect of adjuvant transarterial chemoembolization (TACE) for Barcelona Clinic ...

E-mail: [email protected] Cancer Immunol Res 2025;13:162–70 Current address for T. Kobayashi: Department of Neurosurgery, Tokyo Women's Medical University, Tokyo, Japan.

7 Center for Stem Cell and Regenerative Medicine, Zhejiang University School of Medicine, Hangzhou, China Objective Hepatocellular carcinoma (HCC) is heterogeneous, especially in multifocal tumours, ...

Feb. 7, 2025 — Pancreatic cancer patients may benefit from future precision treatments as a new study shows how some tumors may potentially be more susceptible to ... Personalized Cancer ...

It’s a sobering statistic: 1 in 8 women in the United States will be diagnosed with breast cancer during her lifetime. 1 Breast cancer remains both the most common cancer in women and one of the ...

At this time, he had not heard of any plans for the facilities. An innovative new cancer treatment is available for the first time ever in Iowa. UnityPoint in Des Moines is offering Gamma-Tile ...